Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
41
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Mayo Clinic